Back to top
more

Incyte (INCY)

(Delayed Data from NSDQ)

$76.13 USD

76.13
2,260,926

+2.01 (2.71%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $75.81 -0.32 (-0.42%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's What Key Metrics Tell Us About Incyte (INCY) Q4 Earnings

by Zacks Equity Research

The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Incyte (INCY) Lags Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Incyte (INCY) delivered earnings and revenue surprises of -12.40% and 0.74%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Drug, Biotech Stocks' Q4 Earnings Due on Feb 13: BIIB, ZTS & INCY

by Zacks Equity Research

Let's take a look at three biotech/drug companies, BIIB, ZTS, and INCY, slated to release quarterly results on Feb 13.

Incyte (INCY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Incyte's (INCY) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition recently.

Ahead of Incyte (INCY) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Incyte (INCY) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Novartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology Drug

by Zacks Equity Research

Novartis (NVS) announces an agreement to acquire Germany-based MorphoSys AG and add the latter's late-stage candidate pelabresib to its pipeline.

Incyte (INCY) Banks on Opzelura as Jakafi Faces Competition

by Zacks Equity Research

Incyte (INCY) is likely to rebound in 2024 on the solid growth of Opzelura and additional label expansions.

IDEAYA Biosciences, Inc. (IDYA) Moves 7.6% Higher: Will This Strength Last?

by Zacks Equity Research

IDEAYA Biosciences, Inc. (IDYA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Sarepta Therapeutics (SRPT) Up 4.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?

by Zacks Equity Research

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug

by Zacks Equity Research

Mesoblast (MESO) partners with Blood and Marrow Transplant Clinical Trials Network to develop a pivotal study on its lead candidate, Ryoncil, for acute graft versus host disease. The stock rises 11%.

MorphoSys (MOR) Down 22% on Mixed Data From Myelofibrosis Study

by Zacks Equity Research

Though data from the late study shows that treatment with MorphoSys' (MOR) combination therapy met its primary goal, it did not meet a secondary endpoint.

Incyte (INCY) Beats on Q3 Earnings, Misses Revenue Estimates

by Zacks Equity Research

Incyte's (INCY) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens Jakafi net product revenue guidance for 2023.

Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Incyte (INCY) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

Incyte (INCY) delivered earnings and revenue surprises of 0.92% and 5.58%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Drug, Biotech Stocks' Q3 Earnings Due on Oct 31: AMGN, PFE, INCY

by Zacks Equity Research

Let's take a look at three biotech/drug companies, AMGN, PFE and INCY, slated to release quarterly results on Oct 31.

Incyte (INCY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of lead drug Jakafi and incremental sales of newly approved drugs are likely to have boosted Incyte's (INCY) top line during the third quarter of 2023.

Sarepta Therapeutics (SRPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Incyte (INCY) Stock Plummets 29.6% Year to Date: Here's Why

by Zacks Equity Research

Incyte (INCY) loses 29.6% year-to-date as competition increases for Jakafi and the company suffers pipeline setbacks.

AbbVie's (ABBV) Rinvoq Meets Key Goal in Phase II Vitiligo Study

by Zacks Equity Research

AbbVie (ABBV) meets the primary goal in the phase II study evaluating Rinvoq in the treatment of adult patients with non-segmental vitiligo.

Incyte (INCY) Posts Upbeat Data From Phase II Vitiligo Study

by Zacks Equity Research

Incyte (INCY) announces new positive 52-week data from its mid-stage study of povorcitinib for the treatment of adult patients with extensive nonsegmental vitiligo.

Incyte (INCY) Down on FDA Nod for Another Myelofibrosis Drug

by Zacks Equity Research

Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.

Why Is Incyte (INCY) Down 0.7% Since Last Earnings Report?

by Zacks Equity Research

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MacroGenics' (MGNX) Shares Jump 19% in One Week: Here's Why

by Zacks Equity Research

MacroGenics (MGNX) shares increase after it reported a surge in Q2 earnings per share. A $50-million milestone payment from Sanofi was also triggered last month.

Incyte (INCY) Beats on Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Incyte (INCY) reports impressive Q2 earnings on strong uptake in Jakafi and Opzelura sales. The company raises the bottom end of full-year guidance, setting a new range of $2.58-$2.63 billion.